Literature DB >> 27552677

Potential drug-drug interaction in Mexican patients with schizophrenia.

María Conchita Ocaña-Zurita1, Isela E Juárez-Rojop1, Alma Genis2, Carlos Alfonso Tovilla-Zárate1, Thelma Beatriz González-Castro1, María Lilia López-Narváez3, María Elena de la O de la O1, Humberto Nicolini2.   

Abstract

OBJECTIVE: The aim of this study was to observe potential drug-drug interactions in the medication of Mexican schizophrenic patients.
METHODS: We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software ( http://www.drugs.com/drug_interactions.html ) was used in this study to analyse potential drug-drug interactions.
RESULTS: In total, 86 of 126 patients were at risk of potential drug-drug interactions. Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated. In our study, 13.8% of drug-drug interaction showed a major level of severity, whereas in 83.2%, the interaction was moderate. Finally, central nervous system (CNS) depression and anticholinergic effect were the main possible effects of drug-drug interaction.
CONCLUSIONS: Our results revealed a high number of patients with schizophrenia receiving two or more drugs. The potential drug-drug interactions observed in the Mexican population are consistent with the concomitant use of antipsychotics, benzodiazepines, and antidepressants prescribed in schizophrenia that could cause central nervous system (CNS) depression and anticholinergic effect. Drug-drug interaction must be considered when the patient with schizophrenia is medicated.

Entities:  

Keywords:  Drug–drug interaction; Mexican population; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27552677     DOI: 10.1080/13651501.2016.1213854

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  3 in total

1.  Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones.

Authors:  Natália Fernandes Mezzomo; Izaviani da Silva Schmitz; Valtieri Bortoluzzi de Lima; Gilson Pires Dorneles; Larissa Finger Schaffer; Carina Rodrigues Boeck; Pedro Roosevelt Torres Romao; Luis Ricardo Peroza
Journal:  Mol Biol Rep       Date:  2021-12-01       Impact factor: 2.316

2.  Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.

Authors:  Yu Liu; Man Yang; Yaping Ding; Huanqiang Wang; Hailin Zhang; Dandan Wang; Tianchi Zhuang; Minghui Ji; Yan Cui; Hong Wang
Journal:  BMC Psychiatry       Date:  2022-08-22       Impact factor: 4.144

3.  Increasing the Effectiveness of Pharmacotherapy in Psychiatry by Using a Pharmacological Interaction Database.

Authors:  Michal Ordak; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.